var title_f33_33_34320="Component separation technique plane of dissection";
var content_f33_33_34320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76185&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Component separation technique plane of dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 507px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the plane of dissection between the external oblique muscle and internal oblique muscle for performing the component separation technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34320=[""].join("\n");
var outline_f33_33_34320=null;
var title_f33_33_34321="Patient information: Intussusception (The Basics)";
var content_f33_33_34321=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16959\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?6/39/6770\">",
"         Patient information: Small bowel obstruction (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Intussusception (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/intussusception-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H7191772\">",
"      <span class=\"h1\">",
"       What is intussusception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Intussusception is a condition that can cause severe belly pain. It happens when 1 part of the intestine slides into another part of the intestine. Intussusception can happen with either the small or large intestine (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"mobipreview.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      When 1 part of the intestine slides into another, it causes a blockage. When the intestine is blocked, air, fluid, and food get stuck. They can&rsquo;t move through the intestine the way they normally would. This causes symptoms.",
"     </p>",
"     <p>",
"      Intussusception happens most often in children, especially in children younger than 3 years old. In some cases, intussusception is caused by another medical condition. But in most cases, doctors don&rsquo;t know what caused the intussusception.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7191787\">",
"      <span class=\"h1\">",
"       What are the symptoms of an intussusception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms usually start suddenly and can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Severe belly pain &ndash; The pain comes in waves. At first, episodes of pain happen about every 15 to 20 minutes, but the episodes get closer over time. The pain usually makes children cry and pull their knees up into their belly.",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Bloody bowel movements",
"       </li>",
"       <li>",
"        Being very sleepy and hard to wake up",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Although uncommon, some children with a small intussusception do not have any symptoms. Their doctor might see that they have an intussusception when the child has a test for another reason. Children who have no symptoms might not need treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7191802\">",
"      <span class=\"h1\">",
"       Should my child see the doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Call your child&rsquo;s doctor or nurse right away if your child has symptoms of an intussusception.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7191817\">",
"      <span class=\"h1\">",
"       Is there a test for an intussusception?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your child&rsquo;s symptoms and do an exam. He or she will do an imaging test of the belly, such as an X-ray or ultrasound. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7191832\">",
"      <span class=\"h1\">",
"       How is an intussusception treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor will do a few things to treat your child&rsquo;s intussusception.",
"     </p>",
"     <p>",
"      He or she will give your child fluids into his or her vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      He or she will also put a thin tube called a &ldquo;nasogastric tube&rdquo; in your child&rsquo;s nose, down the esophagus, and into the stomach. The tube will suck up the fluid and air in the stomach. This will make your child feel better and keep him or her from vomiting.",
"     </p>",
"     <p>",
"      After that, the doctor will fix the intussusception. There are different ways to do this. They include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A procedure called &ldquo;nonoperative reduction&rdquo; &ndash; This is not surgery. For this procedure, the doctor will put a tube into your child&rsquo;s rectum and push air or a special fluid into the tube. The air or fluid will go into the rectum and through the intestine. As the air or fluid reaches the intussusception, it makes the stuck intestine slide back out of the other part of the intestine. To follow what he or she is doing, the doctor will do an ultrasound or X-ray during this procedure.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery &ndash; If the intussusception could not be fixed with the nonoperative reduction, or if the intussusception has caused problems, your child will probably need surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H7191847\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/39/6770?source=see_link\">",
"       Patient information: Small bowel obstruction (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/33/34321?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16959 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-0639592F6A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34321=[""].join("\n");
var outline_f33_33_34321=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191772\">",
"      What is intussusception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191787\">",
"      What are the symptoms of an intussusception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191802\">",
"      Should my child see the doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191817\">",
"      Is there a test for an intussusception?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191832\">",
"      How is an intussusception treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7191847\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16959\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/39/6770?source=related_link\">",
"      Patient information: Small bowel obstruction (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_33_34322="Mild tinea barbae";
var content_f33_33_34322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild tinea barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Tinea barbae typically presents as a pustular rash in the beard region of the face, but early or mild cases may not show pustules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34322=[""].join("\n");
var outline_f33_33_34322=null;
var title_f33_33_34323="Grade II nipple inversion";
var content_f33_33_34323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F64187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F64187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grade II nipple inversion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In patients with grade II nipple inversion, forceful manipulation is required to pull the nipple out, and retraction recurs quickly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34323=[""].join("\n");
var outline_f33_33_34323=null;
var title_f33_33_34324="Acetaminophen and pamabrom: Patient drug information";
var content_f33_33_34324=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen and pamabrom: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/3/7220?source=see_link\">",
"     see \"Acetaminophen and pamabrom: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6834944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cramp Tabs [OTC];",
"     </li>",
"     <li>",
"      Midol&reg; Teen Formula [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Women&rsquo;s Menstrual Relief [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease painful period (menstrual) cycles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, pamabrom, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11256 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-46FA143880-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34324=[""].join("\n");
var outline_f33_33_34324=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6834944\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026531\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026530\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026535\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026536\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026538\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026533\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026534\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026539\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026540\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/3/7220?source=related_link\">",
"      Acetaminophen and pamabrom: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_33_34325="Spine anatomy MRI";
var content_f33_33_34325=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Spine anatomy MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 640px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal MRI study shows the primary contents of the vertebral canal. The medullary cone (L. conus medullaris) is the cone-shaped inferior end of the spinal cord, which typically ends at the L1&ndash;L2 level in adults. The dura mater, the external overing of the spinal cord (gray), is separated from the spinal cord by a fluid-filled space (black) and from the wall of the vertebral canal by fat (white) and thin-walled veins (not visible here).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34325=[""].join("\n");
var outline_f33_33_34325=null;
var title_f33_33_34326="Hydrocodone and homatropine: Drug information";
var content_f33_33_34326=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hydrocodone and homatropine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/24/30084?source=see_link\">",
"    see \"Hydrocodone and homatropine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hydromet&reg;;",
"     </li>",
"     <li>",
"      Tussigon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F180133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F180124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antitussive:",
"     </b>",
"     Oral: 1 tablet or 5 mL every 4-6 hours as needed (maximum: 6 tablets/24 hours or 30 mL/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F180129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antitussive:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years:",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet or 2.5 mL every 4-6 hours as needed (maximum: 3 tablets or 15 mL/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F180125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F180110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup: Hydrocodone bitartrate 5 mg and homatropine methylbromide 1.5 mg per 5 mL (473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hydromet&reg;: Hydrocodone bitartrate 5 mg and homatropine methylbromide 1.5 mg per 5 mL (480 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tussigon&reg;: Hydrocodone bitartrate 5 mg and homatropine methylbromide 1.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F180094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Syrup",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F180135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7282725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To prevent overdose, administer oral solution with an accurate measuring device (not a household teaspoon).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F180111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of cough",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F180141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hycodan may be confused with Vicodin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F180131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, drowsiness, dysphoria, fear, lethargy, mental clouding, mental impairment, mood changes, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention, urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Physical and psychological dependence with prolonged use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Cardiorespiratory arrest",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F180115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hydrocodone, homatropine, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F180098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (codeine, hydromorphone, levorphanol, morphine, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure/glaucoma: Use with caution in patients with increased intraocular pressure or glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pulmonary disease or decrease ventilatory function; dose-related respiratory depression occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;poor metabolizers&rdquo;: Due to the role of CYP2D6 in the metabolism of hydrocodone to hydromorphone (an active metabolite with higher binding affinity to mu-opioid receptors compared to hydrocodone), patients with genetic variations of CYP2D6, including &ldquo;poor metabolizers&rdquo; or &ldquo;extensive metabolizers,&rdquo; may have decreased or increased hydromorphone formation, respectively. Variable effects in positive and negative opioid effects have been reported in these patients; however, limited data exists to determine if clinically significant differences of analgesia and toxicity can be predicted based on CYP2D6 phenotype (Hutchinson, 2004; Otton, 1993; Zhou, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in children; may be more sensitive to adverse effects. Safety and efficacy of this combination have not been established in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postoperative patients: Use with caution postoperatively; causes respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough: Appropriate use: Underlying cause of cough should be determined prior to prescribing.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F180130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F180103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease serum concentrations of the active metabolite(s) of Hydrocodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F180119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F180105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3090299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Birth defects, including some heart defects, have been associated with maternal use of opioid analgesics, including hydrocodone, during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate. Symptoms of opioid withdrawal may include excessive crying, diarrhea, fever, hyper-reflexia, irritability, respiratory rate increased, sneezing, tremors, vomiting, or yawning; respiratory depression may occur in the newborn if opioids are used prior to delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F180126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5630829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hydrocodone is excreted in breast milk; information for homatropine is not available. In one study, the calculated dose of hydrocodone to a nursing infant was 0.2% to 9% (mean: 2.4%) of the weight-adjusted maternal dose. Hydromorphone was also measurable in 12 cases; the total opioid dose to a nursing infant was calculated to be 0.1% to 9.9% (mean: 1.5%) of the weight-adjusted maternal dose. Concentrations may be increased in women who are extensive metabolizers of CYP2D6. Caution should be used since most persons are not aware of their CYP2D6 genotype status. When hydrocodone is used in breast-feeding women, it is recommended to use the lowest dose for the shortest duration of time and observe the infant for adverse events. Some clinicians recommend limiting the dose to hydrocodone bitartrate 30 mg/day (Sauberan, 2011). The manufacturers recommend discontinuing the medication or to discontinue nursing during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F180116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Hydrocodone-Homatropine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1.5 mg/5 mL (473 mL): $87.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hydrocodone-Homatropine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1.5 mg (30): $18.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tussigon Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1.5 mg (100): $72.23",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Hydromet (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F180097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hydrocodone binds to opiate receptors in the CNS, altering the perception of and response to pain; suppresses cough in medullary center; produces generalized CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Homatropine is an anticholinergic agent, present in a subtherapeutic amount to discourage deliberate overdose.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13831156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Homatropine:",
"     </b>",
"     See Homatropine monograph.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hydrocodone:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onset of action: Narcotic analgesic: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Duration: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Metabolism: Hepatic; O-demethylation via primarily CYP2D6 to hydromorphone (major, active metabolite with ~10- to 33-fold higher or as much as a &gt;100-fold higher binding affinity for the mu-opioid receptor than hydrocodone); N-demethylation via CYP3A4 to norhydrocodone (major metabolite); and ~40% of metabolism/clearance occurs via other non-CYP pathways, including 6-ketosteroid reduction to 6-alpha-hydrocol and 6-beta-hydrocol, and other elimination pathways (eg, fecal, biliary, intestinal, renal) (Hutchinson, 2004; Volpe, 2011; Zhou, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Half-life elimination: 3.3-4.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Excretion: Urine (26% of single dose in 72 hours, with ~12% as unchanged drug, 5% as norhydrocodone, 4% as conjugated hydrocodone, 3% as 6-hydrocodol, and 0.21% as conjugated 6-hydromorphol (Zhou, 2009)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson PO, Sauberan JB, Lane JR, et al, &ldquo;Hydrocodone Excretion Into Breast Milk: The First Two Reported Cases,&rdquo;",
"      <i>",
"       Breastfeed Med",
"      </i>",
"      , 2007, 2(1):10-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/17661614/pubmed\" id=\"17661614\" target=\"_blank\">",
"        17661614",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"National Birth Defects Prevention Study: Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hutchinson MR, Menelaou A, Foster DJ, et al, &ldquo;CYP2D6 and CYP3A4 Involvement in the Primary Oxidative Metabolism of Hydrocodone by Human Liver Microsomes,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 2004, 57(3):287-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/14998425/pubmed\" id=\"14998425\" target=\"_blank\">",
"        14998425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina DK and Hargrove VM, &ldquo;What Is the Lethal Concentration of Hydrocodone?,&rdquo;",
"      <i>",
"       Am J Forensic Med Pathol",
"      </i>",
"      , 32(2):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/20407360/pubmed\" id=\"20407360\" target=\"_blank\">",
"        20407360",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Otton SV, Schadel M, Cheung SW, et al, &ldquo;CYP2D6 Phenotype Determines the Metabolic Conversion of Hydrocodone to Hydromorphone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1993, 54(5):463-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/7693389/pubmed\" id=\"7693389\" target=\"_blank\">",
"        7693389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, &ldquo;Management of Nonobstetric Pain During Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sauberan JB, Anderson PO, Lane JR, et al, \"Breast Milk Hydrocodone and Hydromorphone Levels in Mothers Using Hydrocodone for Postpartum Pain,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2011, 117(3):611-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/21343764/pubmed\" id=\"21343764\" target=\"_blank\">",
"        21343764",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Volpe DA, McMahon Tobin GA, Mellon RD, et al, &ldquo;Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs,&rdquo;",
"      <i>",
"       Regul Toxicol Pharmacol",
"      </i>",
"      , 2011, 59(3):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/21215785 /pubmed\" id=\"21215785 \" target=\"_blank\">",
"        21215785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhou SF, &ldquo;Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2009, 48(12):761-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/33/34326/abstract-text/19902987/pubmed\" id=\"19902987\" target=\"_blank\">",
"        19902987",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8534 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-59FAC149C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34326=[""].join("\n");
var outline_f33_33_34326=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180133\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180124\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180129\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180125\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897561\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897562\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180110\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180135\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7282725\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180111\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180141\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180131\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180115\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180098\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180130\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180103\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180119\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180105\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3090299\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180126\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5630829\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180116\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539876\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180097\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13831156\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8534\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8534|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/24/30084?source=related_link\">",
"      Hydrocodone and homatropine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_33_34327="Herpes simplex virus hand";
var content_f33_33_34327=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62720%7EPC%2F73975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62720%7EPC%2F73975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex virus infection of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Close-up view of vesicles on an erythematous base.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Herpes simplex labialis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Grouped vesicles are evident on the lower vermilion border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley LS, Szilagyi P. Bates' Guide to Physical Examination and History Taking, Eighth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34327=[""].join("\n");
var outline_f33_33_34327=null;
var title_f33_33_34328="Mobitz type II second degree atrioventricular block";
var content_f33_33_34328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1083px;\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Mobitz type II second degree atrioventricular (AV) block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 142px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The third and sixth P waves are not conducted through the AV node (there is no associated QRS complex). The PR interval is constant prior to and after the non-conducted beats.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 456px\">",
"   <div class=\"ttl\">",
"    Sinus rhythm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 103px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The normal P wave in sinus rhythm is slightly notched since activation of the right atrium precedes that of the left atrium. The P wave is upright in a positive direction in leads I and II. A P wave with a uniform morphology precedes each QRS complex. The rate is between 60 and 100 beats per minute and the cycle length is uniform between sequential P waves and QRS complexes. In addition, the P wave morphology and PR intervals are identical from beat to beat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34328=[""].join("\n");
var outline_f33_33_34328=null;
var title_f33_33_34329="Classic Kaposi sarcoma - papules and plaques";
var content_f33_33_34329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69584%7EDERM%2F81468%7EDERM%2F54707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69584%7EDERM%2F81468%7EDERM%2F54707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple violaceous papules and plaques are present on the distal upper extremity of this patient with classic Kaposi sarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple red-brown patches and plaques are present on the lower leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classic Kaposi sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple papules and nodules are present on the lower leg in this patient with classic Kaposi sarcoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34329=[""].join("\n");
var outline_f33_33_34329=null;
var title_f33_33_34330="Specific therapies for sickle cell disease";
var content_f33_33_34330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Specific therapies for sickle cell disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Griffin P Rodgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/33/34330/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/33/34330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of morbidity and mortality in sickle cell disease (SCD) are the acute and long-term consequences of vasoocclusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of vasoocclusion is the result of a number of factors, beginning with the polymerization of deoxyhemoglobin S and ending with the subsequent interactions between the sickled erythrocyte and the vascular endothelium. Factors that influence such hemoglobin polymerization include cellular dehydration, which increases the concentration of sickle hemoglobin (HbS) and the sickling process, the level of gamma globin chains, which inhibit the polymerization of HbS, intracellular acidosis, and oxygen saturation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Agents that have been specifically employed in SCD to decrease these processes will be reviewed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/1\">",
"     1",
"    </a>",
"    ]. Overviews of the treatment of SCD and the use of hematopoietic cell transplantation, the only curative treatment for SCD, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive cure is not currently available for most patients with SCD. Gene therapy for SCD is especially formidable, due to the difficulty in transducing hematopoietic stem cells and the necessity for erythroid-specific, high level, and balanced globin gene expression. As a result, increasing attention has been focused on the use of hematopoietic cell transplantation. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Gene therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H23\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, these more aggressive therapies should be reserved for patients at high risk, since the mean survival in SCD is currently 42 years in men and 48 years in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/2\">",
"     2",
"    </a>",
"    ]. A number of studies have attempted to identify such factors. In one report of 392 children, for example, three adverse factors were identified before the age of two (dactylitis, leukocytosis in the absence of infection, and a hemoglobin concentration less than 7",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/3\">",
"     3",
"    </a>",
"    ]. The false positive rate was only 1 percent but these factors only identified 20 percent of the children who had an adverse outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the management of sickle cell disease\", section on 'Prediction of adverse outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less aggressive therapies for SCD are aimed largely at symptom control during painful vasoocclusive episodes (previously called sickle cell crises) and at the prevention of symptoms by prophylactic blood transfusion to lower the HbS concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link\">",
"     \"Overview of the management of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a number of therapeutic strategies have been designed to interfere with the polymerization process at different levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/5\">",
"     5",
"    </a>",
"    ]. The opportunity for effective intervention at different points in the pathogenetic pathway strongly suggests that the combination of two or more agents, each with a different mechanism of action, might be additive and perhaps synergistic, similar to multidrug regimens for hypertension and cancer chemotherapy.",
"   </p>",
"   <p>",
"    However, at present,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    is the only major medical modality with proven efficacy in patients with frequent symptoms related to SCD and many of the agents described below, with the exception of hydroxyurea and hematopoietic cell transplantation, are mainly of historic interest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REACTIVATING FETAL HEMOGLOBIN SYNTHESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protective effect of fetal hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enhanced concentrations of hemoglobin F have, in most studies, a marked inhibitory effect on sickling and improve the clinical course of SCD. This is attested to by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In certain populations, such as Bedouin Arabs from the Saudi peninsula, certain tribes from Central India, and Senegalese, patients homozygous for SCD have relatively high amounts of hemoglobin F and relatively mild clinical manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/6-9\">",
"       6-9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cooperative study of the natural history of patients with SCD in the United States, the frequency of pain crises correlated inversely with the HbF concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a mouse model of SCD, progressive increases in hemoglobin F from &lt;3 to 40 percent correlated with a progressive increase in hematocrit, decrease in reticulocytosis, improved urinary concentrating ability, and reduced tissue damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For these reasons, there has been a search for pharmacologic agents capable of stimulating hemoglobin F production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/1,12-16\">",
"     1,12-16",
"    </a>",
"    ]. There are at least two ways in which this might be achieved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct activation of the respective promoter genes appears to be the mechanism by which 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"       azacytidine",
"      </a>",
"      and butyric acid and its derivatives increase HbF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythropoietin and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      seem to work by recruitment into proliferation and differentiation of a population of erythroid precursors which retain the gamma-chain synthesis program but remain dormant in the bone marrow of the adult unless called up in cases of acute erythroid expansion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While several of these agents can increase the level of hemoglobin F, only",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    has shown significant clinical effects in terms of reduction of pain crises, chest syndrome, and transfusions in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HYDROXYUREA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antitumor drugs, in particular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (hydroxycarbamide, Droxia&reg;, Hydrea&reg;), increase production of hemoglobin F in primates and in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. The molecular mechanism through which this occurs is not fully understood, but hydroxyurea may selectively increase G gamma, as opposed to A gamma, fetal hemoglobin mRNA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/22\">",
"     22",
"    </a>",
"    ], perhaps in part through release of nitric oxide and stimulation of soluble guanylyl cyclase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/23\">",
"     23",
"    </a>",
"    ]. This selective regulation of individual fetal hemoglobins parallels that seen in human development, where approximately 70 percent of the total fetal hemoglobin in the fetus is G gamma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H558387868\">",
"    <span class=\"h2\">",
"     Indications and clinical benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    is indicated in patients with SCD with one or more of the following problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Frequent painful episodes",
"     </li>",
"     <li>",
"      History of acute chest syndrome",
"     </li>",
"     <li>",
"      History of other severe vasoocclusive events",
"     </li>",
"     <li>",
"      Severe symptomatic anemia",
"     </li>",
"     <li>",
"      Very young children (see",
"      <a class=\"local\" href=\"#H8373714\">",
"       'Very young children and the BABY HUG trial'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Mechanism of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is generally assumed that the beneficial effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in patients with SCD are due to the induction of hemoglobin F, most likely related to an effect on genes regulating transcription and translation, including BCL11A, a key regulator of baseline HbF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Increasing expression of HbF'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other factors also may play a role, such as the generation of nitric oxide (NO) by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , which may, in part, reverse the depletion of this potent pulmonary vasodilator caused by red cell hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/23,27-31\">",
"     23,27-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H20#H20\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Mechanism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed multivariate analysis of data from the Multicenter Study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    in Sickle Cell Anemia (MSH) showed that the percentage of F-cells correlated inversely with the rate of pain crises only during the initial three months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast, there was a strong correlation between the neutrophil count and crisis rate throughout the two-year study. However, the dose of hydroxyurea was titrated to the neutrophil count, raising the possibility of an ascertainment bias.",
"   </p>",
"   <p>",
"    Nonetheless, the modest neutropenia that accompanies",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    therapy may contribute, most likely in a secondary manner, to the drug's efficacy. This finding may be linked to the experimental observations that neutrophils from patients with SCD have enhanced binding to fibronectin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/33\">",
"     33",
"    </a>",
"    ] and increased activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, neutropenia may reduce the inflammation associated with ischemic events. However, a nine-year follow-up to the MSH trial found no relationship between decrements in the neutrophil count and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    therapy also may be due in part to a reduction in reticulocytes and young, low density HbSS red cells, since these cells are particularly likely to adhere to vascular endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Among patients treated with hydroxyurea, adhesion of the patients' red cells to cultured endothelial cells decreased markedly within two weeks, long before there was a significant induction of hemoglobin F [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/36\">",
"     36",
"    </a>",
"    ]. In similar studies, adhesion of HbSS red cells in vitro to immobilized subendothelial matrix proteins thrombospondin and laminin was significantly decreased following treatment with hydroxyurea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link&amp;anchor=H17#H17\">",
"     \"Vasoocclusion in sickle cell disease\", section on 'Sickle cell adhesion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    partially suppresses erythropoiesis, this reduction of young adherent cells is accompanied by only a modest increase in red cell mass. A full compensatory response to the reduction in hemolysis might have adverse rheologic consequences, due to increases in total hemoglobin and hematocrit, thereby increasing overall blood viscosity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hematologic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    is currently the only drug in widespread use for stimulating hemoglobin F production in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. It is relatively nontoxic, its myelosuppressive effects are readily reversible, and it is not known to induce tumors, although it appears to increase the incidence of acute myeloid leukemia when used in patients with the malignant myeloproliferative neoplasms polycythemia vera and essential thrombocythemia. Accordingly, long-term follow-up for the development of malignancy in patients with SCD treated with this agent is a major priority [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=see_link&amp;anchor=H15#H15\">",
"     \"Prognosis and treatment of polycythemia vera\", section on 'Hydroxyurea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=see_link&amp;anchor=H12#H12\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Leukemogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The great majority of patients with SCD who are given doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    sufficient to cause mild myelosuppression have a marked increase in HbF-containing red cells, the percent HbF, and the HbF concentration per cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/20,21,45-49\">",
"     20,21,45-49",
"    </a>",
"    ]. In one study of 32 patients treated with hydroxyurea, (mean oral single daily dose of 21",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for at least 16 weeks), the mean HbF concentration rose from a pretreatment value of approximately 4 percent to 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HUG-KIDS trial explored predictors of HbF response in 53 school-aged children with SCD, treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    at maximally tolerated doses (MTD) for one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/50\">",
"     50",
"    </a>",
"    ]. Median HbF levels at baseline and at MTD were 5.5 and 17.6 percent, respectively. Predictors of those most likely to have a robust increase in HbF response at MTD included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher percent HbF at baseline",
"     </li>",
"     <li>",
"      Higher baseline reticulocyte count",
"     </li>",
"     <li>",
"      Higher baseline white blood cell count",
"     </li>",
"     <li>",
"      Higher maximally tolerated dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"     </li>",
"     <li>",
"      Better compliance (fewer unused pills returned at follow-up)",
"     </li>",
"     <li>",
"      Greater treatment-related increases in hemoglobin concentration and mean corpuscular volume",
"     </li>",
"     <li>",
"      Greater treatment-related decreases in white blood cell count and reticulocyte percentage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increase in HbF following treatment with this agent is accompanied by a reduction in hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/51\">",
"     51",
"    </a>",
"    ], a modest increase in hemoglobin concentration, a significant decrease in irreversibly sickled cells and dense cells, as well as a reduction of in vitro measurements of sickling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/47\">",
"     47",
"    </a>",
"    ] and erythrocyte-endothelial adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=see_link\">",
"     \"Vasoocclusion in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609480611\">",
"    <span class=\"h3\">",
"     Studies in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of studies have demonstrated the benefit of using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    to minimize severe clinical events in infants, children, and adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/32,35,42,49,53-61\">",
"     32,35,42,49,53-61",
"    </a>",
"    ]. The highest-grade evidence for these benefits comes from a multicenter, two-year, double-blind, randomized, placebo-controlled trial of hydroxyurea in 299 adults with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/53\">",
"     53",
"    </a>",
"    ]. The trial was stopped earlier than expected after the demonstration that active therapy reduced the median crisis rate by almost 50 percent (2.5 versus 4.5 crises per year). Hydroxyurea was relatively well tolerated, was associated with a decreased incidence of acute chest syndrome, a reduction in the need for transfusions, and was cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/32,53,57\">",
"     32,53,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the end of the formal portion of this trial, participants were given the choice to continue taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , switch to this agent if they had received placebo, or receive supportive care only. Follow-up data are now available for up to nine years in 233 of the original subjects. The most significant findings were [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patients with absolute reticulocyte counts",
"      <span class=\"nowrap\">",
"       &lt;250,000/microL",
"      </span>",
"      and hemoglobin levels &lt;9.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      had increased mortality.",
"     </li>",
"     <li>",
"      Cumulative mortality at nine years was 28 versus 15 percent when absolute HbF levels, after the trial was completed, were &lt;0.5 versus &ge;0.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      Mortality was 32 versus 18 percent, respectively, for those who had or did not have acute chest syndrome during the trial.",
"     </li>",
"     <li>",
"      Mortality was 27 versus 17 percent, respectively, for those who had &ge;3 versus &lt;3 painful",
"      <span class=\"nowrap\">",
"       episodes/year",
"      </span>",
"      during the trial.",
"     </li>",
"     <li>",
"      Taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      was associated with a 40 percent reduction in mortality.",
"     </li>",
"     <li>",
"      There were three cases of cancer (cervix, breast, uterus), one of which was fatal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A prospective, non-randomized study evaluated the long-term efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU) in adult patients (median age: 42 years, range: 20 to 76) with",
"    <span class=\"nowrap\">",
"     HbS/HbS,",
"    </span>",
"    <span class=\"nowrap\">",
"     HbS/beta(0)",
"    </span>",
"    thalassemia, and",
"    <span class=\"nowrap\">",
"     HbS/beta(+)",
"    </span>",
"    thalassemia. At a median follow-up of eight years for HU-treated patients and five years for non-HU patients, the following major findings were noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/61\">",
"     61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment with HU was associated with dramatic reductions in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome.",
"     </li>",
"     <li>",
"      The 10-year probabilities of survival for those with",
"      <span class=\"nowrap\">",
"       HbS/HbS,",
"      </span>",
"      <span class=\"nowrap\">",
"       HbS/beta(0)",
"      </span>",
"      thal, and",
"      <span class=\"nowrap\">",
"       HbS/beta(+)",
"      </span>",
"      thal who were treated with HU were 100, 87, and 82 percent, respectively. The corresponding 10-year survivals for those not treated with HU were 10, 54, and 66 percent, respectively.",
"     </li>",
"     <li>",
"      During follow-up there were no cases of myelodysplasia or cancer in either group of patients. No children born to subjects who were taking treatment with HU had birth defects or other problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many patients with sickle cell disease still die of complications of their disease while being treated with HU. In one study, of the 226 patients treated with HU, 38 died (34 of SCD-related causes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/62\">",
"     62",
"    </a>",
"    ]. Deceased patients were significantly older at the time HU therapy was initiated, were more anemic, more likely to have a Bantu or Cameroon beta globin gene haplotype, and had significantly higher serum BUN and creatinine levels. Editorials, reviews, an NIH Consensus Conference, as well as a survey of community-based hematologist-oncologists have strongly suggested that many patients who might benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    receive this therapy in a sub-optimal manner, too late in the course of their disease, or perhaps not at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/41,42,63-68\">",
"     41,42,63-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609480618\">",
"    <span class=\"h3\">",
"     Studies in children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefits similar to those seen in adults were noted in a long-term follow-up of 93 children and young adults with severe SCD who were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU) for up to six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/58\">",
"     58",
"    </a>",
"    ]. At a median follow-up of 3.5 years, all patients were still alive; the median number of hospitalizations dropped from two per year before HU to zero during subsequent years. During the first year of treatment, 84 percent were free of vasoocclusive crises; these percentages were 79, 81, 90, and 74 percent for years two through five, respectively. Neither opportunistic infection, malignancy, nor major toxicity of HU was noted.",
"   </p>",
"   <p>",
"    A follow-up study in 127 children confirmed the long-term (up to eight years) efficacy of HU in preventing hospitalizations due to vasoocclusive events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/69\">",
"     69",
"    </a>",
"    ]. Although HU was not used in maximally tolerated doses in this study, all ages appeared to benefit, with the exception of those less than two years of age, who remained at risk for severe anemia. There was one case of malignancy, acute promyelocytic leukemia, occurring in a 21-year-old female following eight years of treatment with HU. Two patients became pregnant while taking HU and gave birth to healthy babies.",
"   </p>",
"   <p>",
"    A smaller pilot trial (HUSOFT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     HydroxyUrea",
"    </a>",
"    Safety and Organ Toxicity) demonstrated the benefit and safety of HU at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two years in 21 infants with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/70\">",
"     70",
"    </a>",
"    ]. In this trial, and in an extension in which the participants were treated for as long as six years at a dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/59\">",
"     59",
"    </a>",
"    ], benefits included increased hemoglobin concentration, lowered reticulocyte percentage, improved splenic function and growth rates, as well as a lower incidence of acute chest syndrome events. Treatment was well tolerated.",
"   </p>",
"   <p>",
"    The HbF response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    is variable and complex, however, and even children with low baseline percent HbF levels can develop substantial increases in HbF when taking this agent at maximally tolerated doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/50\">",
"     50",
"    </a>",
"    ]. There is evidence that at least some of this variability in response to hydroxyurea is under genetic control. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Response to hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pilot trial in 14 young children (mean age 35 months) has shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    at a mean maximum tolerated dose of 28",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day was well-tolerated by children and their families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/71\">",
"     71",
"    </a>",
"    ]. After a mean of 25 months of treatment, no child had conditional or abnormal transcranial Doppler values and none developed brain ischemic lesions. Growth and neurocognitive scores were preserved and impact-on-family scores improved.",
"   </p>",
"   <p>",
"    A retrospective cohort study compared quality of life issues in 191 children with sickle cell disease. Those in the group treated with HU reported better overall health-related quality of life (HRQL) and better physical HRQL than children who did not receive this therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8373714\">",
"    <span class=\"h4\">",
"     Very young children and the BABY HUG trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BABY HUG Trial (NCT00006400) is a multicenter, randomized, double-blind placebo-controlled trial to test whether treating young children (ages 9 to 18 months at entry) with HbSS or HbS-beta(0) thalassemia with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    can decrease organ damage in the kidneys (assessed by DTPA glomerular filtration rate) and spleen (assessed by Tc",
"    <sup>",
"     99m",
"    </sup>",
"    splenic scanning) by at least 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/73\">",
"     73",
"    </a>",
"    ]. Of importance, participants in this study were not selected for clinical severity. Hydroxyurea was given at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and followed at that dose for two years, using an oral liquid solution not commercially available at this time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A total of 167 children (HU: 83, placebo: 84) completed the study, with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significant differences were not seen between groups for the primary endpoints.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Decreased splenic function from baseline was seen in 27 versus 38 percent of those in the HU and placebo groups, respectively.",
"     </li>",
"     <li>",
"      The difference in the mean increase in DTPA glomerular filtration rate in the HU versus placebo group was 2",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HU significantly decreased the number of pain events (177 events in 62 children versus 375 events in 75 children, p = 0.002) and dactylitis (24 events in 14 children versus 123 events in 42 children, p &lt; 0.0001).",
"     </li>",
"     <li>",
"      For secondary endpoints, the planned level of statistical significance was p = 0.01. Treatment with HU resulted in nonstatistically significant decreases in the occurrence of acute chest syndrome (p = 0.02), hospital admissions (p = 0.05), and transfusion (p = 0.03), and in significantly better levels of hemoglobin (p &lt; 0.0001) and fetal hemoglobin (p &lt; 0.0001) at the end of the trial.",
"     </li>",
"     <li>",
"      Toxicity was limited to mild-to-moderate neutropenia. There was no increase in the incidence of serious infections and no deaths during the reporting period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The collection of event data has been extended in the BABY HUG Follow-up Study until 2016.",
"   </p>",
"   <p>",
"    This agent is currently offered at St. Jude Children&rsquo;s Research Hospital to children with pain or acute chest syndrome as young as two years of age. Experience-based, rather than evidence-based, consensus criteria at St. Jude for initiating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    treatment for children over the age of 24 months and adolescents with sickle cell anemia include presence of the following complications, in an attempt to prevent future organ damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain, including dactylitis",
"     </li>",
"     <li>",
"      Acute chest syndrome",
"     </li>",
"     <li>",
"      Low hemoglobin; low percent hemoglobin F",
"     </li>",
"     <li>",
"      Elevated white blood cell count, elevated lactate dehydrogenase",
"     </li>",
"     <li>",
"      Abnormal transcranial Doppler values in subjects refusing blood transfusion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence-based information from the BABY HUG trial strongly supports the St. Jude approach, extending it to even younger children, and further suggests that HU could now be considered for the treatment of",
"    <strong>",
"     all",
"    </strong>",
"    very young children with sickle cell anemia, regardless of clinical severity. The importance of this issue is highlighted by baseline information from the BABY HUG trial that splenic function was decreased or absent in 88 percent of the participants before treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    was begun [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H12679833#H12679833\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Reduced or absent splenic function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11095754\">",
"    <span class=\"h5\">",
"     Caveat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until a liquid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    becomes commercially available, an oral solution can be prepared from commercially available capsules that is chemically and functionally stable at room temperature for several months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/74\">",
"     74",
"    </a>",
"    ]. Issues concerning access to a reliable compounding pharmacy for preparation of the oral solution, long-term follow-up, approval from the US Food and Drug Administration for this indication, and third party reimbursement need to be settled before comprehensive implementation of this therapy can be expected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dosing recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the HUG-KIDS trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    was started at a dose of 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in a single oral dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/50\">",
"     50",
"    </a>",
"    ]. Blood counts were routinely monitored for the presence of cytopenias, and the dose escalated every 8 weeks to the maximum tolerated dose or to a maximum dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Since accurate pharmacokinetic prediction of the effects and toxicity of hydroxyurea are unavailable at present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/78\">",
"     78",
"    </a>",
"    ], this standardized dose escalation to mild myelosuppression is currently the best dosing option.",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    was given in a fixed dose of 20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in the BABY HUG trial, in patients deemed candidates for this agent, we suggest beginning dosing at 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information on the use of this medication can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=see_link&amp;anchor=H10#H10\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Hydroxyurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently available guidelines for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    dosing include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/24,41,63\">",
"     24,41,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Required baseline information includes a complete blood count with red cell indices, percent hemoglobin F, serum chemistries. Since animal studies have demonstrated teratogenicity and embryotoxicity, a pregnancy test for female patients should be obtained and subsequent pregnancy is not advised.",
"     </li>",
"     <li>",
"      The suggested initial dose is 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in a single oral dose. For patients with a creatinine clearance &lt;60",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      the starting dose should be 7.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Specific guidelines are not available for dosage adjustment in hepatic impairment.",
"     </li>",
"     <li>",
"      Peripheral blood counts should be obtained every two weeks, serum chemistries every two to four weeks, and hemoglobin F every six to eight weeks. The drug should be temporarily stopped if the absolute neutrophil count is &lt;2000 microL, the platelet count is",
"      <span class=\"nowrap\">",
"       &lt;80,000/microL,",
"      </span>",
"      the hemoglobin &lt;4.5",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      or the absolute reticulocyte count",
"      <span class=\"nowrap\">",
"       &lt;80,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      If there is no major toxicity, the dose should be increased every 6 to 12 weeks by 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day until the desired endpoint is reached (ie, a maximum dose of 30 to 35",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or unacceptable degrees of cytopenia).",
"     </li>",
"     <li>",
"      After a stable dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      has been achieved, blood counts and serum chemistries should be obtained every four to eight weeks to follow hepatic and renal function. Hemoglobin F levels should be obtained every three to four months to assess treatment efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Long-term toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As experience with long-term treatment of patients with SCD with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU) increases, there is appropriate concern about the possible induction of tumors, including acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. The potential degree of risk was evaluated in a study of patients with essential thrombocythemia treated with HU; there was a 3.5 percent risk of leukemic transformation, along with rearrangements of chromosome 17 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/79\">",
"     79",
"    </a>",
"    ]. However, essential thrombocythemia is one of the myeloproliferative neoplasms (MPNs), all of which have an inherent tendency to develop acute leukemia at some time during their course. Accordingly, the leukemogenicity of HU in the MPNs may not be applicable to a nonmalignant condition such as SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=see_link&amp;anchor=H12#H12\">",
"     \"Prognosis and treatment of essential thrombocythemia\", section on 'Leukemogenicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of developing a malignancy in patients with SCD treated with HU was evaluated in a number of reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 233 evaluable adults first entered into the MSH trial and in whom follow-up data were available nine years after the trial started, three patients developed cancer (one each: breast, cervix, uterus) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/35\">",
"       35",
"      </a>",
"      ]. At least one of the three patients had a preexisting condition placing her at increased risk for cancer. A subsequent report at 17.5 years of follow-up revealed no additional cases, with an overall rate of malignancy of 0.1 per 100 patient-years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term toxicity in SCD was also assessed in 122 children treated with HU at maximally tolerated doses (average dose 25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for an average duration of 45 months (range: 0.5 to 8.4 years) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/55\">",
"       55",
"      </a>",
"      ]. There was no adverse effect on growth as determined by serial measurements of height and weight; some children experienced improved growth while taking this medication. Testing in 26 children with five years of exposure to HU did not disclose any increase in the average number of acquired illegitimate immunoglobulin VDJ rearrangements, a sensitive test for acquired somatic mutations. No child acquired myelodysplasia, leukemia, or any malignancy during this period. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=see_link\">",
"       \"Immunoglobulin genetics\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study, aspects of chromosomal damage and repair were studied in vitro in peripheral blood mononuclear cells from 51 children with SCD (mean age: 13.2 years) who had been treated with HU for 3 to 12 years. Results were compared with similar cellular studies performed in a group of 28 children with SCD (mean age: 9.4 years) prior to any treatment with this agent, as well as with 11 normal adult healthy controls (mean age: 44 years). Results included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chromosomal damage",
"      <span class=\"nowrap\">",
"       (breaks/100",
"      </span>",
"      cells) was significantly less in the HU treated group than in children not treated with HU (0.8 versus 1.9), and similar to that seen in the normal adult controls (0.6).",
"     </li>",
"     <li>",
"      There were no significant differences in repairing chromosomal breaks after in vitro irradiation among the three groups.",
"     </li>",
"     <li>",
"      Irradiation plus incubation with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      resulted in a similar number of unrepaired breaks in HU-treated children when compared with children not receiving HU or in the normal controls. No differences were noted in the number of chromosomal breaks between those treated with HU for three to six years versus those treated with HU for 9 to 12 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations provide further evidence that long-term treatment with HU is associated with low mutagenicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     5-AZACYTIDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In erythroid cells, with the developmental switch from gamma globin (HbF) to beta globin (HbA) production in the newborn period, the inactive gamma gene becomes methylated and the actively expressed beta globin gene becomes hypomethylated. Since 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacytidine",
"    </a>",
"    is an antineoplastic drug that inhibits maintenance methylation of DNA, it was hoped that use of this agent would hypomethylate the gamma globin gene and reactivate HbF production.",
"   </p>",
"   <p>",
"    The administration of 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacytidine",
"    </a>",
"    caused a marked increase in hemoglobin F in baboons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/82\">",
"     82",
"    </a>",
"    ]. These results prompted limited clinical trials that demonstrated significant, but less dramatic, induction of hemoglobin F production in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/83,84\">",
"     83,84",
"    </a>",
"    ], although the exact mechanism through which this agent increased HbF levels was uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     5-Aza deoxycytidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The related drug, 5-aza-2'-deoxycytidine (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ; given at a dose of 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously one to three times per week in two cycles of six-weeks duration) has shown efficacy in short- and long-term trials in increasing HbF levels and total hemoglobin levels in patients failing to respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. HbF levels as high as 20 percent have been noted after such treatment. Other than mild neutropenia, no untoward effects were noted. Long-term effects of such treatment are not yet known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ERYTHROPOIETIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of concerns about long-term administration of an antitumor drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/40/12935?source=see_link\">",
"     azacytidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ) to patients with a congenital non-malignant disorder, there is considerable interest in identifying safe alternatives for inducing HbF production. Although initial reports suggested that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/48/2825?source=see_link\">",
"     recombinant human erythropoietin",
"    </a>",
"    (rhEpo) stimulated HbF production in patients with SCD, subsequent clinical studies both with rhEpo alone and in combination with standard doses of hydroxyurea have produced conflicting results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/47,90-93\">",
"     47,90-93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study concerning the combined use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and erythropoietin was reported from the National Institutes of Health and included a literature review of the subject [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/94\">",
"     94",
"    </a>",
"    ]. This report concluded that EPO may be considered as an adjunct to HU therapy in patients with high risk SCD, anemia, low reticulocyte counts, and deteriorating renal function, particularly when HU therapy is limited by the erythroid reserve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     BUTYRIC ACID",
"    </span>",
"    &nbsp;&mdash;&nbsp;The butyrates are perhaps the first class of drugs designed to transcriptionally activate specific genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/95\">",
"     95",
"    </a>",
"    ]. Butyrate and related drugs stimulate fetal gamma globin expression in erythroid cells cultured from patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/96\">",
"     96",
"    </a>",
"    ]. In addition, infusions of sodium butyrate into sheep fetuses and normal baboons increase HbF production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. It has been suggested that exposure to butyrate, a known histone deacetylase inhibitor, results in a true reversal of the normal developmental switch from gamma- to beta-globin expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/100\">",
"     100",
"    </a>",
"    ]. This is associated with increased histone acetylation and decreased DNA methylation of the gamma-globin genes, with opposite changes in the beta-globin gene.",
"   </p>",
"   <p>",
"    However, there are conflicting reports regarding the efficacy of butyrate therapy in patients with beta thalassemia and SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Analogs of butyrate (eg, arginine butyrate) as well as acetate and other short chain fatty acid derivatives also appear to induce HbF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/103-106\">",
"     103-106",
"    </a>",
"    ]. More studies are needed to assess the efficacy and safety of these potentially nonteratogenic and nonmutagenic means of inducing HbF production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIRECT CHEMICAL INHIBITION OF POLYMERIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of sickling could work either by increasing oxygen affinity, thereby reducing the relative amounts of deoxyhemoglobin S in the red cell, or by binding to contact sites on the HbS fiber, inhibiting polymer assembly",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    growth.",
"   </p>",
"   <p>",
"    As an example of the first approach, in vivo administration of gaseous nitric oxide increases the whole blood oxygen affinity of sickle erythrocytes with no effect on blood containing only normal hemoglobin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/107\">",
"     107",
"    </a>",
"    ]. This approach is problematic since it is likely that any compound that increases oxygen affinity will stimulate red cell production. There is good clinical evidence that an increase in red cell mass has a negative impact upon the clinical course of SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As examples of the second approach, compounds are being evaluated that directly inhibit hemoglobin polymerization in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/108-110\">",
"     108-110",
"    </a>",
"    ]. To be effective, the drug will have to be readily absorbed from the gastrointestinal tract, circulate in plasma without binding to plasma proteins, penetrate the red blood cell membrane, and inhibit polymerization without having a deleterious effect upon oxygen transport. Compounds that bind covalently to hemoglobin are more likely to bind with high affinity. Delivered quantities of the drug will have to be large, since the body pool of hemoglobin that will require such binding approximates 400 grams.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     REDUCING INTRACELLULAR HEMOGLOBIN CONCENTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of polymerization of deoxygenated HbS is dependent upon the HbS concentration. Polymerization-induced membrane damage, leading to enhanced dehydration, results in the presence of a substantial population of very dense cells. These dense cells are much more prone to sickle and contribute disproportionately to the vasoocclusive aspects of the disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mechanism of erythrocyte dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dehydration in sickle erythrocytes is due to the loss of potassium, chloride, and water from the erythrocyte. Two ion transport pathways, K-Cl cotransport and a calcium-activated potassium channel, play a prominent role in this process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In normal red cells, the K-Cl cotransporter is activated only in reticulocytes. Transport rates are much higher in sickle red cells due in part to chronic hemolysis, an increase in the population of young cells, and induction of the cotransporter by acidification or urea, particularly at sites of stagnant circulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/113,114\">",
"       113,114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    K-Cl cotransport in normal erythrocytes is inhibited by low oxygen tension and is refractory to stimulation by low pH or urea; in contrast, the activity of the transporter in sickle erythrocytes is independent of oxygen tension and retains the ability to be activated by low pH and urea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. As a result, the K-Cl cotransporter in sickle erythrocytes can induce significant potassium, chloride, and water loss even at a low PO2, as occurs, for example, in the renal medulla. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=see_link\">",
"     \"Renal manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The second pathway for cellular dehydration is sickling-induced loss of potassium and water through the calcium-dependent (Gardos) potassium channel. Although sickle red cells have an increased calcium content, the steady state cytosolic calcium concentration is normal because of compartmentalization of the increased calcium within intracellular vesicles [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/117\">",
"       117",
"      </a>",
"      ]. However, when the cell membrane is distorted by sickling, cytosolic calcium transiently increases and activates the potassium channel with consequent loss of potassium and water from the cell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In vitro studies suggest that both the K-Cl cotransporter and calcium-dependent potassium channel contribute to the cellular dehydration associated with sickled cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/112\">",
"     112",
"    </a>",
"    ]. The majority of irreversibly sickled cells, which contribute to vasoocclusion, are markedly dehydrated (hyperdense), a process that seems more dependent upon the Gardos channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/112\">",
"     112",
"    </a>",
"    ]. Gardos channel activity and cell density of sickle erythrocytes can be significantly increased in vitro by a number of cytokines (eg, endothelin, platelet activator factor, IL-10, RANTES), suggesting that similar red cell changes might occur in vivo following activation of vascular endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/119\">",
"     119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Lowering hemoglobin concentration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapeutic approaches have attempted to lower sickle cell hemoglobin concentration by dilution. The first was the induction of hypotonicity (ie, hyponatremia) with concomitant cell swelling via the administration of dDAVP and a high water intake [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/120\">",
"     120",
"    </a>",
"    ]. Although this treatment is effective, it requires careful and continuous monitoring of the plasma sodium concentration and is too cumbersome and risky to be used on a routine outpatient basis. Some progress, however, has been made in the development of drugs that inhibit potassium and chloride loss from the sickle red cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/121\">",
"     121",
"    </a>",
"    ]. This can be achieved by inhibition of the Gardos channel, K-Cl cotransport (eg, magnesium), or, in theory, the anion conductance that operates in parallel with the Gardos channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/122-124\">",
"     122-124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Inhibiting the transport channels",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the reasons enumerated above, inhibition of the Gardos channel might have a beneficial effect on SCD by improving the hydration state of red cells, thereby reducing HbS polymer formation. Two agents that inhibit this channel are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Clotrimazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gardos channel is specifically inhibited by the antifungal drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/18/33056?source=see_link\">",
"     clotrimazole",
"    </a>",
"    . The efficacy of this drug has been demonstrated by in vitro incubation experiments, studies in transgenic mice with SCD, and observations in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. One report evaluated five patients who were treated with clotrimazole (20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day); the red cell Gardos channel was inhibited, cell potassium content increased, and the red cells became less dehydrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/127\">",
"     127",
"    </a>",
"    ]. At the end of this short-term study, there was a modest increase in hemoglobin levels and a significant reduction in serum indirect bilirubin concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Senicapoc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Senicapoc (ICA-17043) is a highly potent Gardos channel blocking agent that has specifically inhibited the efflux of potassium from red cells of transgenic HbSS mice as well as red cells from human subjects with SCD. In a randomized placebo-controlled phase II study, a dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of senicapoc raised hemoglobin levels (the primary study endpoint) in patients with HbSS by an average of 0.6",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (95% CI 0.3-1.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/128\">",
"     128",
"    </a>",
"    ]. Significant improvements in hematocrit and reticulocyte count, and significant reductions in percent dense red cells, indirect bilirubin, and lactate dehydrogenase were also seen.",
"   </p>",
"   <p>",
"    Side effects were rated as mild or moderate. However, a phase III trial of this agent in patients with SCD was terminated due to the low probability of achieving a reduction in painful crisis rate, the primary endpoint of that study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytosolic magnesium modulates calcium and potassium channels in a variety of tissues. Intracellular divalent cations, particularly magnesium, effectively retard potassium and water loss from HbSS red cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/130\">",
"     130",
"    </a>",
"    ]. In addition, in vivo administration of a high magnesium diet to transgenic mice with SCD increased erythrocyte magnesium and potassium content and reduced K-Cl cotransport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/131\">",
"     131",
"    </a>",
"    ]. The associated increase in cell volume led to reductions in mean corpuscular hemoglobin concentration and cell density. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16085?source=see_link\">",
"     \"Significance of hypomagnesemia in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential clinical utility of this approach was assessed in patients with SCD who were treated with oral magnesium supplementation (0.6",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    per day of magnesium pidolate) and studied after four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/132\">",
"     132",
"    </a>",
"    ] and six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/133\">",
"     133",
"    </a>",
"    ]. Erythrocyte K-Cl cotransport was reduced significantly, sickle erythrocyte magnesium and potassium content rose, and the number of dense sickle erythrocytes was reduced; the last effect may have been due to an increase in cell volume. Similar beneficial effects of magnesium supplementation have been noted in patients with beta thalassemia intermedia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether these changes would result in a significant increase in circulating levels of hemoglobin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have important clinical effects with long-term therapy have yet to be determined. In a preliminary report, the cellular changes induced by oral magnesium supplements were associated with a significant reduction in the number of painful crises [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HEMATOPOIETIC CELL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) currently offers the only hope for cure of SCD, although the reported experience is limited. The selection of patients is an important unresolved issue because of the variability of the disease and the lack of prognostic factors. Other important issues relate to the mortality associated with the procedure and the potential for treatment-induced malignancy. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCT for SCD is still under careful evaluation in the United States. Many physicians taking care of patients with SCD have adopted a wait-and-see approach to HCT because of the uncertainties concerning patient selection, the risks associated with the procedure, the variable clinical course with medical therapy, and the promise for better medical therapies as described in this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although still experimental, gene therapy has the potential to cure SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/136,137\">",
"     136,137",
"    </a>",
"    ]. Expression of the human sickle gene in transgenic mice and creation of plasmids with the human beta globin locus are examples of the possible feasibility of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/138-141\">",
"     138-141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Increasing expression of HbF",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, higher levels of HbF are associated with reduced disease severity in patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. Studies in mouse models have shown the utility of this approach. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Reactivating fetal hemoglobin synthesis'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Fetal hemoglobin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SAD mouse model of SCD produces polymerized hemoglobin and exhibits many of the features of SCD seen in patients. To test the efficacy of increasing levels of HbF, SAD mice were mated with transgenic mice that overexpress different levels of the human A gamma globin gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/142\">",
"       142",
"      </a>",
"      ]. Expression of 9 to 16 percent HbF was sufficient to produce a significant therapeutic effect, with improvements in all hematologic parameters and survival.",
"     </li>",
"     <li>",
"      Forced expression of the nuclear receptors TR2 and TR4 enhances the expression of fetal gamma-globin gene expression in murine adult erythroid cells. Such forced expression was also able to increase HbF from 7.6 to 18.6 percent of total hemoglobin in a humanized sickle cell mouse model, along with improvement in hemolytic anemia and other pathologic defects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/143\">",
"       143",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The transcription factor BCL11A (B-cell",
"      <span class=\"nowrap\">",
"       lymphoma/leukemia",
"      </span>",
"      11A) is a known repressor of HbF expression, and controls the developmental switch from embryonic to adult beta-globin in the mouse as well as in cultured primary human erythroid cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/144\">",
"       144",
"      </a>",
"      ]. Inactivation of BCL11A in SCD transgenic mice corrected the hematologic and pathologic defects associated with SCD through high-level pancellular induction of HbF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/145\">",
"       145",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link&amp;anchor=H10340141#H10340141\">",
"       \"Structure and function of normal human hemoglobins\", section on 'Transition from HbF to HbA'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The latter two approaches, if they can be duplicated in man, have the ability to drastically alter the clinical course of sickle cell disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     RNA repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative genetic approach is to use ribozymes, which are small RNA molecules that can specifically bind to complimentary RNA sequences and catalyze the cleavage of the target RNA, to increase the expression of HbF",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce that of HbS via RNA repair [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/146,147\">",
"     146,147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one in vitro model, for example, a trans-splicing group I ribozyme was used to alter mutant beta globin constructs in erythrocyte precursors derived from the peripheral blood of patients with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/146\">",
"     146",
"    </a>",
"    ]. Sickle beta globin transcripts were converted into messenger RNAs encoding gamma globin. In another model, ribozymes were used to decrease the concentration of sickle beta globin chains and mRNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of this approach will depend upon the ability to develop suitable vectors and optimization of constructs to permit a clinically relevant increase in protein expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/148\">",
"     148",
"    </a>",
"    ]. Efficiency does not have to be 100 percent as evidenced by the observation that sickle cell trait, in which the concentration of HbS is approximately 50 percent of total hemoglobin, is a benign condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OTHER TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Nicosan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only one herbal agent tested to date, nicosan (Niprisan&reg;, Hemoxin, Nix-0699), has proved to have an",
"    <span class=\"nowrap\">",
"     efficacy/toxicity",
"    </span>",
"    ratio sufficiently high to merit testing in clinical trials. Nicosan is a plant extract that has been successfully used in Nigeria to prevent painful crises associated with SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/1,149-152\">",
"     1,149-152",
"    </a>",
"    ]. Although its exact mechanism of action, active ingredient(s), and long-term side effects are unknown, nicosan inhibits sickling in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/153\">",
"     153",
"    </a>",
"    ], as well as in vivo in a transgenic mouse model of SCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although nicosan has been granted orphan drug status by the United States FDA and the European Medicine Evaluation Agency, a commercial supplier of this agent has not yet been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/33/34330/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"       \"Patient information: Sickle cell anemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the present time, only hematopoietic cell transplantation offers a cure for patients with sickle cell disease (SCD), while",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    is the only major medical modality with proven efficacy in patients with frequent symptoms related to SCD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for hematopoietic cell transplantation in patients with sickle cell disease have included the presence of severe debilitating clinical events such as stroke, recurrent acute chest syndrome, and recurrent painful vaso-occlusive crises. This procedure, which can be associated with considerable morbidity and mortality, has been generally limited to children and young adults with an HLA-matched sibling donor. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Hematopoietic cell transplantation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=see_link\">",
"     \"Hematopoietic cell transplantation in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Treatment with hydroxyurea",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children and adults",
"      </strong>",
"      &mdash; In children older than two years of age and adults with sickle cell disease who have frequent painful episodes, severe symptomatic anemia, or a history of acute chest syndrome or other severe vasoocclusive events, we recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This agent should be continued for as long as it is tolerated and effective. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hydroxyurea'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The recommended initial oral dose of hydroxyurea for children and adults with a creatinine clearance &gt;60",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      is 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. Subsequent dose increments are determined by the patient's response. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Dosing recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Very young children",
"      </strong>",
"      &mdash; We suggest that all very young children (ie, 9 to 18 months of age) with sickle cell disease, independent of disease severity, be treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (dose: 15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8373714\">",
"       'Very young children and the BABY HUG trial'",
"      </a>",
"      above.) Compounding pharmacy support is required until a liquid formulation becomes commercially available. (See",
"      <a class=\"local\" href=\"#H11095754\">",
"       'Caveat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There is no information on the safety and efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      in children younger than nine months of age. However, given the high prevalence of splenic damage prior to nine months of age, we suggest the use of hydroxyurea in children younger than nine months of age with symptomatic disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H12679833#H12679833\">",
"       \"Overview of the clinical manifestations of sickle cell disease\", section on 'Reduced or absent splenic function'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In children who have been started on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      in this age range who remain asymptomatic or minimally symptomatic, while awaiting additional data, we suggest continuing hydroxyurea indefinitely, with close monitoring as outlined below (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Children and adults with minimal disease activity",
"      </strong>",
"      &mdash; In adults and children who are substantially older than 18 months of age and who have been asymptomatic or minimally symptomatic without treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      , we suggest not starting hydroxyurea (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )",
"      <strong>",
"       .",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Monitoring &mdash;",
"      </strong>",
"      For both children and adults, close monitoring of the patient is essential for the success of this agent. Studies to be performed before and during treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      include a complete blood count with red cell indices, white blood cell differential, platelet count, reticulocyte percentage, and serum chemistries for evaluation of renal and hepatic function. A pregnancy test for female patients should be obtained.",
"     </li>",
"     <li>",
"      <strong>",
"       Ancillary treatments",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Although data are sparse concerning its benefit, we suggest the addition of erythropoietin in patients not responding to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Erythropoietin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transfusion with packed red blood cells should be given when symptomatic anemia is present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of the management of sickle cell disease\", section on 'Transfusion therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/1\">",
"      Hankins J, Aygun B. Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol 2009; 145:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/2\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/3\">",
"      Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/4\">",
"      Castro O. Management of sickle cell disease: recent advances and controversies. Br J Haematol 1999; 107:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/5\">",
"      Vichinsky E. New therapies in sickle cell disease. Lancet 2002; 360:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/6\">",
"      Perrine RP, Pembrey ME, John P, et al. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med 1978; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/7\">",
"      Wood WG, Pembrey ME, Serjeant GR, et al. Hb F synthesis in sickle cell anaemia: a comparison of Saudi Arab cases with those of African origin. Br J Haematol 1980; 45:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/8\">",
"      Brittenham G, Lozoff B, Harris JW, et al. Sickle cell anemia and trait in southern India: further studies. Am J Hematol 1979; 6:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/9\">",
"      Diop S, Thiam D, Cisse M, et al. New results in clinical severity of homozygous sickle cell anemia, in Dakar, Senegal. Hematol Cell Ther 1999; 41:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/10\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/11\">",
"      Fabry ME, Suzuka SM, Weinberg RS, et al. Second generation knockout sickle mice: the effect of HbF. Blood 2001; 97:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/12\">",
"      Jane SM, Cunningham JM. Understanding fetal globin gene expression: a step towards effective HbF reactivation in haemoglobinopathies. Br J Haematol 1998; 102:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/13\">",
"      Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore) 2001; 80:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/14\">",
"      Mischiati C, Sereni A, Lampronti I, et al. Rapamycin-mediated induction of gamma-globin mRNA accumulation in human erythroid cells. Br J Haematol 2004; 126:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/15\">",
"      Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/16\">",
"      Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the &beta;-globin disorders. Blood 2012; 120:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/17\">",
"      Saunthararajah Y, Lavelle D, DeSimone J. DNA hypo-methylating agents and sickle cell disease. Br J Haematol 2004; 126:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/18\">",
"      Trompeter S, Roberts I. Haemoglobin F modulation in childhood sickle cell disease. Br J Haematol 2009; 144:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/19\">",
"      Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/20\">",
"      Dover GJ, Humphries RK, Moore JG, et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 1986; 67:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/21\">",
"      Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987; 69:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/22\">",
"      Xu J, Zimmer DB. Differential regulation of A gamma and G gamma fetal hemoglobin mRNA levels by hydroxyurea and butyrate. Exp Hematol 1998; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/23\">",
"      Cokic VP, Smith RD, Beleslin-Cokic BB, et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J Clin Invest 2003; 111:231.",
"     </a>",
"    </li>",
"    <li>",
"     The management of sickle cell disease. National Institutes of Health; National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources. NIH publication 04-2117, revised 2004. This reference is available for downloading or purchase at: &lt;www.nhlbi.nih.gov/health/prof/blood/sickle/&gt;. (Accessed on April 1, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/25\">",
"      Costa FC, da Cunha AF, Fattori A, et al. Gene expression profiles of erythroid precursors characterise several mechanisms of the action of hydroxycarbamide in sickle cell anaemia. Br J Haematol 2007; 136:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/26\">",
"      Flanagan JM, Steward S, Howard TA, et al. Hydroxycarbamide alters erythroid gene expression in children with sickle cell anaemia. Br J Haematol 2012; 157:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/27\">",
"      Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 2002; 116:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/28\">",
"      Nahavandi M, Tavakkoli F, Wyche MQ, et al. Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea. Br J Haematol 2002; 119:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/29\">",
"      Iyamu EW, Cecil R, Parkin L, et al. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Br J Haematol 2005; 131:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/30\">",
"      Cokic VP, Beleslin-Cokic BB, Tomic M, et al. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood 2006; 108:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/31\">",
"      Westerman M, Pizzey A, Hirschman J, et al. Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapy. Br J Haematol 2008; 142:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/32\">",
"      Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \"switching\" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine (Baltimore) 1996; 75:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/33\">",
"      Kasschau MR, Barabino GA, Bridges KR, Golan DE. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996; 87:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/34\">",
"      Benkerrou M, Delarche C, Brahimi L, et al. Hydroxyurea corrects the dysregulated L-selectin expression and increased H(2)O(2) production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 2002; 99:2297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/35\">",
"      Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003; 289:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/36\">",
"      Bridges KR, Barabino GD, Brugnara C, et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 1996; 88:4701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/37\">",
"      Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol 1997; 98:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/38\">",
"      Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases the in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/39\">",
"      Bartolucci P, Chaar V, Picot J, et al. Decreased sickle red blood cell adhesion to laminin by hydroxyurea is associated with inhibition of Lu/BCAM protein phosphorylation. Blood 2010; 116:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/40\">",
"      Halsey C, Roberts IA. The role of hydroxyurea in sickle cell disease. Br J Haematol 2003; 120:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/41\">",
"      Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med 2008; 148:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/42\">",
"      Lanzkron S, Strouse JJ, Wilson R, et al. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med 2008; 148:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/43\">",
"      Berlin N, Berlin NI. Polycythemia vera. Hematol Oncol Clin North Am 2003; 17:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/44\">",
"      Ferster A, Sariban E, Meuleman N, Belgian Registry of Sickle Cell Disease patients treated with Hydroxyurea. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 2003; 123:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/45\">",
"      Ballas SK, Dover GJ, Charache S. Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo. Am J Hematol 1989; 32:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/46\">",
"      Rodgers GP, Dover GJ, Noguchi CT, et al. Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea. N Engl J Med 1990; 322:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/47\">",
"      Goldberg MA, Brugnara C, Dover GJ, et al. Treatment of sickle cell anemia with hydroxyurea and erythropoietin. N Engl J Med 1990; 323:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/48\">",
"      Orringer EP, Blythe DS, Johnson AE, et al. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia. Blood 1991; 78:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/49\">",
"      Charache S, Dover GJ, Moore RD, et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992; 79:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/50\">",
"      Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002; 99:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/51\">",
"      Franco RS, Yasin Z, Palascak MB, et al. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood 2006; 108:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/52\">",
"      Setty BN, Kulkarni S, Dampier CD, Stuart MJ. Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood 2001; 97:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/53\">",
"      Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/54\">",
"      Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/55\">",
"      Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004; 103:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/56\">",
"      Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database Syst Rev 2001; :CD002202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/57\">",
"      Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/58\">",
"      Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001; 97:3628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/59\">",
"      Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 2005; 106:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/60\">",
"      Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 2008; 122:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/61\">",
"      Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010; 115:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/62\">",
"      Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 2005; 105:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/63\">",
"      Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/64\">",
"      Steinberg MH. Sickle cell disease and hydroxyurea: the good, the bad, and the future (editorial). Blood 2005; 105:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/65\">",
"      Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol 2005; 79:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/66\">",
"      Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115:5300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/67\">",
"      Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol 2011; 86:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/68\">",
"      Haywood C Jr, Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol 2011; 86:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/69\">",
"      Gulbis B, Haberman D, Dufour D, et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005; 105:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/70\">",
"      Wang WC, Wynn LW, Rogers ZR, et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001; 139:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/71\">",
"      Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer 2009; 52:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/72\">",
"      Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol 2011; 33:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/73\">",
"      Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design. Pediatr Blood Cancer 2010; 54:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/74\">",
"      Heeney MM, Whorton MR, Howard TA, et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 2004; 26:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/75\">",
"      Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/76\">",
"      Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012; 120:4304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/77\">",
"      Rogers ZR, Wang WC, Luo Z, et al. Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood 2011; 117:2614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/78\">",
"      Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118:4985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/79\">",
"      Sterkers Y, Preudhomme C, La&iuml; JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998; 91:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/80\">",
"      Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/81\">",
"      McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol 2011; 154:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/82\">",
"      DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A 1982; 79:4428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/83\">",
"      Ley TJ, DeSimone J, Noguchi CT, et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983; 62:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/84\">",
"      Dover GJ, Charache SH, Boyer SH, et al. 5-Azacytidine increases fetal hemoglobin production in a patient with sickle cell disease. Prog Clin Biol Res 1983; 134:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/85\">",
"      Mabaera R, Greene MR, Richardson CA, et al. Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobin. Blood 2008; 111:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/86\">",
"      Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000; 96:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/87\">",
"      DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 2002; 99:3905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/88\">",
"      Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102:3865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/89\">",
"      Saunthararajah Y, Molokie R, Saraf S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 2008; 141:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/90\">",
"      al-Khatti A, Umemura T, Clow J, et al. Erythropoietin stimulates F-reticulocyte formation in sickle cell anemia. Trans Assoc Am Physicians 1988; 101:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/91\">",
"      Nagel RL, Vichinsky E, Shah M, et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 1993; 81:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/92\">",
"      Rodgers GP, Dover GJ, Uyesaka N, et al. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med 1993; 328:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/93\">",
"      el-Hazmi MA, al-Momen A, Kandaswamy S, et al. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. Acta Haematol 1995; 94:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/94\">",
"      Little JA, McGowan VR, Kato GJ, et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 2006; 91:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/95\">",
"      Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol 1995; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/96\">",
"      Weinberg RS, Ji X, Sutton M, et al. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 2005; 105:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/97\">",
"      Perrine SP, Miller BA, Faller DV, et al. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. Blood 1989; 74:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/98\">",
"      Perrine SP, Rudolph A, Faller DV, et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci U S A 1988; 85:8540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/99\">",
"      Constantoulakis P, Knitter G, Stamatoyannopoulos G. On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC. Blood 1989; 74:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/100\">",
"      Fathallah H, Weinberg RS, Galperin Y, et al. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 2007; 110:3391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/101\">",
"      Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993; 328:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/102\">",
"      Sher GD, Ginder GD, Little J, et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med 1995; 332:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/103\">",
"      Stamatoyannopoulos G, Blau CA, Nakamoto B, et al. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 1994; 84:3198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/104\">",
"      Little JA, Dempsey NJ, Tuchman M, Ginder GD. Metabolic persistence of fetal hemoglobin. Blood 1995; 85:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/105\">",
"      Liakopoulou E, Blau CA, Li Q, et al. Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 1995; 86:3227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/106\">",
"      Reich S, B&uuml;hrer C, Henze G, et al. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood 2000; 96:3357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/107\">",
"      Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997; 100:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/108\">",
"      Cerami A, Manning JM. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro. Proc Natl Acad Sci U S A 1971; 68:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/109\">",
"      Walder JA, Zaugg RH, Walder RY, et al. Diaspirins that cross-link beta chains of hemoglobin: bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate. Biochemistry 1979; 18:4265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/110\">",
"      Abraham DJ, Perutz MF, Phillips SE. Physiological and x-ray studies of potential antisickling agents. Proc Natl Acad Sci U S A 1983; 80:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/111\">",
"      Brugnara C, Bunn HF, Tosteson DC. Regulation of erythrocyte cation and water content in sickle cell anemia. Science 1986; 232:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/112\">",
"      Schwartz RS, Musto S, Fabry ME, Nagel RL. Two distinct pathways mediate the formation of intermediate density cells and hyperdense cells from normal density sickle red blood cells. Blood 1998; 92:4844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/113\">",
"      Canessa M, Spalvins A, Nagel RL. Volume-dependent and NEM-stimulated K+,Cl- transport is elevated in oxygenated SS, SC and CC human red cells. FEBS Lett 1986; 200:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/114\">",
"      Olivieri O, Vitoux D, Galacteros F, et al. Hemoglobin variants and activity of the (K+Cl-) cotransport system in human erythrocytes. Blood 1992; 79:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/115\">",
"      Gibson JS, Speake PF, Ellory JC. Differential oxygen sensitivity of the K+-Cl- cotransporter in normal and sickle human red blood cells. J Physiol 1998; 511 ( Pt 1):225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/116\">",
"      Culliford SJ, Ellory JC, Gibson JS, Speake PF. Effects of urea and oxygen tension on K flux in sickle cells. Pflugers Arch 1998; 435:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/117\">",
"      Lew VL, Hockaday A, Sepulveda MI, et al. Compartmentalization of sickle-cell calcium in endocytic inside-out vesicles. Nature 1985; 315:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/118\">",
"      Lew VL, Ortiz OE, Bookchin RM. Stochastic nature and red cell population distribution of the sickling-induced Ca2+ permeability. J Clin Invest 1997; 99:2727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/119\">",
"      Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002; 99:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/120\">",
"      Rosa RM, Bierer BE, Thomas R, et al. A study of induced hyponatremia in the prevention and treatment of sickle-cell crisis. N Engl J Med 1980; 303:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/121\">",
"      Brugnara C. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Curr Opin Hematol 1995; 2:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/122\">",
"      Bennekou P, Pedersen O, M&oslash;ller A, Christophersen P. Volume control in sickle cells is facilitated by the novel anion conductance inhibitor NS1652. Blood 2000; 95:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/123\">",
"      Bennekou P, de Franceschi L, Pedersen O, et al. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood 2001; 97:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/124\">",
"      Stocker JW, De Franceschi L, McNaughton-Smith GA, et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 2003; 101:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/125\">",
"      Brugnara C, de Franceschi L, Alper SL. Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993; 92:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/126\">",
"      De Franceschi L, Saadane N, Trudel M, et al. Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease. J Clin Invest 1994; 93:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/127\">",
"      Brugnara C, Gee B, Armsby CC, et al. Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1996; 97:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/128\">",
"      Ataga KI, Smith WR, De Castro LM, et al. Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 2008; 111:3991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/129\">",
"      Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011; 153:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/130\">",
"      Brugnara C, Tosteson DC. Inhibition of K transport by divalent cations in sickle erythrocytes. Blood 1987; 70:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/131\">",
"      De Franceschi L, Beuzard Y, Jouault H, Brugnara C. Modulation of erythrocyte potassium chloride cotransport, potassium content, and density by dietary magnesium intake in transgenic SAD mouse. Blood 1996; 88:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/132\">",
"      De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997; 100:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/133\">",
"      De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br J Haematol 2000; 108:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/134\">",
"      De Franceschi L, Cappellini MD, Graziadei G, et al. The effect of dietary magnesium supplementation on the cellular abnormalities of erythrocytes in patients with beta thalassemia intermedia. Haematologica 1998; 83:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/135\">",
"      De Franceschi L, Bachir D, Galacteros F, et al. Dietary magnesium supplementation reduces pain crises in patients with sickle cell disease (abstract). Blood 1997; 90:264a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/136\">",
"      Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001; 294:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/137\">",
"      Mansilla-Soto J, Rivi&egrave;re I, Sadelain M. Genetic strategies for the treatment of sickle cell anaemia. Br J Haematol 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/138\">",
"      Wu LC, Sun CW, Ryan TM, et al. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood 2006; 108:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/139\">",
"      Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/140\">",
"      Perumbeti A, Higashimoto T, Urbinati F, et al. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction. Blood 2009; 114:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/141\">",
"      Zou J, Mali P, Huang X, et al. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. Blood 2011; 118:4599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/142\">",
"      Blouin MJ, Beauchemin H, Wright A, et al. Genetic correction of sickle cell disease: insights using transgenic mouse models. Nat Med 2000; 6:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/143\">",
"      Campbell AD, Cui S, Shi L, et al. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. Proc Natl Acad Sci U S A 2011; 108:18808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/144\">",
"      Wilber A, Hargrove PW, Kim YS, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of &beta;-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 2011; 117:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/145\">",
"      Xu J, Peng C, Sankaran VG, et al. Correction of sickle cell disease in adult mice by interference with fetal hemoglobin silencing. Science 2011; 334:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/146\">",
"      Lan N, Howrey RP, Lee SW, et al. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science 1998; 280:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/147\">",
"      Alami R, Gilman JG, Feng YQ, et al. Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia. Blood Cells Mol Dis 1999; 25:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/148\">",
"      Weatherall DJ. Gene therapy: repairing haemoglobin disorders with ribozymes. Curr Biol 1998; 8:R696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/149\">",
"      Wambebe C, Khamofu H, Momoh JA, et al. Double-blind, placebo-controlled, randomised cross-over clinical trial of NIPRISAN in patients with Sickle Cell Disorder. Phytomedicine 2001; 8:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/150\">",
"      Cordeiro NJ, Oniyangi O. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev 2004; :CD004448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/151\">",
"      Fawibe AE. Managing acute chest syndrome of sickle cell disease in an African setting. Trans R Soc Trop Med Hyg 2008; 102:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/152\">",
"      Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev 2010; :CD004448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/153\">",
"      Iyamu EW, Turner EA, Asakura T. In vitro effects of NIPRISAN (Nix-0699): a naturally occurring, potent antisickling agent. Br J Haematol 2002; 118:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/154\">",
"      Iyamu EW, Turner EA, Asakura T. Niprisan (Nix-0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions. Br J Haematol 2003; 122:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/33/34330/abstract/155\">",
"      Perampaladas K, Masum H, Kapoor A, et al. The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan. BMC Int Health Hum Rights 2010; 10 Suppl 1:S11.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7071 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-3033BD7A4C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34330=[""].join("\n");
var outline_f33_33_34330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REACTIVATING FETAL HEMOGLOBIN SYNTHESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protective effect of fetal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HYDROXYUREA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H558387868\">",
"      Indications and clinical benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hematologic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609480611\">",
"      - Studies in adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609480618\">",
"      - Studies in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8373714\">",
"      Very young children and the BABY HUG trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H11095754\">",
"      - Caveat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dosing recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Long-term toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      5-AZACYTIDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      5-Aza deoxycytidine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ERYTHROPOIETIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      BUTYRIC ACID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIRECT CHEMICAL INHIBITION OF POLYMERIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      REDUCING INTRACELLULAR HEMOGLOBIN CONCENTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mechanism of erythrocyte dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Lowering hemoglobin concentration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Inhibiting the transport channels",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Clotrimazole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Senicapoc",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Magnesium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HEMATOPOIETIC CELL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Increasing expression of HbF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      RNA repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OTHER TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Nicosan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Treatment with hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30775?source=related_link\">",
"      Hematopoietic cell transplantation in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/52/37702?source=related_link\">",
"      Immunoglobulin genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=related_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/28/32202?source=related_link\">",
"      Prognosis and treatment of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/56/28554?source=related_link\">",
"      Prognosis and treatment of polycythemia vera",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/3/6202?source=related_link\">",
"      Renal manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14330?source=related_link\">",
"      Vasoocclusion in sickle cell disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_33_34331="Diagnosis of SCID";
var content_f33_33_34331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for severe combined immunodeficiency (SCID)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definitive diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Male or female patient less than 2 years of",
"age with either (a) engraftment of transplacentally acquired maternal T",
"cells or (b) less than 20 percent CD3+ T cells, an absolute lymphocyte",
"count of less than 3000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , and at least one of the following:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Mutation in the cytokine common gamma chain (&Gamma;c).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Mutation in JAK3.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Mutation in RAG1 or RAG2.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. Mutation in",
"IL-7R&alpha;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. ADA activity of less than 2 percent of control or mutations",
"in both alleles of ADA.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probable diagnosis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Male or female patient less than 2 years of age with (a) less than",
"20 percent CD3+ T cells, an absolute lymphocyte count of less than",
"3000/mm",
"        <sup>",
"         3",
"        </sup>",
"        , and proliferative responses to mitogens less than 10 percent",
"of control or (b) the presence of maternal lymphocytes in the",
"circulation.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Patients with a definitive or probable diagnosis are assumed to have a greater than 98 and 85 percent probability, respectively, that in 20 years they will still have the same diagnosis.",
"    </div>",
"    <div class=\"reference\">",
"     From Conley, ME, Notarangelo, LD, Etzioni, A. Clin Immunol 1999; 93:190.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34331=[""].join("\n");
var outline_f33_33_34331=null;
var title_f33_33_34332="T4 RIA with anti T4 antibodies";
var content_f33_33_34332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F75308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F75308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radioimmunoassay curve for T4 with anti-T4 antibodies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 257px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    If endogenous human anti-T4 antibodies are present and bind radiolabeled T4 (*T4) then the amount of *T4 that binds to rabbit anti-T4 antibody and then is precipitated by goat anti-rabbit gamma globulin is reduced. Low percent *T4 binding correlates with high serum concentrations of T4, giving a spuriously high result.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34332=[""].join("\n");
var outline_f33_33_34332=null;
var title_f33_33_34333="Clinical features myoclonus";
var content_f33_33_34333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F51170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F51170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of specific types of myoclonus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distribution",
"       </td>",
"       <td class=\"subtitle1\">",
"        Temporal profile",
"       </td>",
"       <td class=\"subtitle1\">",
"        Activation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical neurophysiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Anatomic-physiologic classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical-etiologic classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Specific etiology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypnic jerks (massive myoclonus of sleep)",
"       </td>",
"       <td>",
"        Generalized",
"       </td>",
"       <td>",
"        Usually single",
"       </td>",
"       <td>",
"        Occur only during sleep or sleep transitions",
"       </td>",
"       <td>",
"        Not studied",
"       </td>",
"       <td>",
"        Presumed subcortical-nonsegmental",
"       </td>",
"       <td>",
"        Physiologic",
"       </td>",
"       <td>",
"        Normal phenomenon",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Partial myoclonic jerks (of sleep)",
"       </td>",
"       <td>",
"        Multifocal, distal muscles",
"       </td>",
"       <td>",
"        Usually single",
"       </td>",
"       <td>",
"        Occur only during sleep or sleep transitions",
"       </td>",
"       <td>",
"        Not studied",
"       </td>",
"       <td>",
"        Presumed subcortical-nonsegmental",
"       </td>",
"       <td>",
"        Physiologic",
"       </td>",
"       <td>",
"        Normal phenomenon",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Myoclonus-dystonia",
"       </td>",
"       <td>",
"        Neck, trunk, proximal arms",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Rest, action, and posture",
"       </td>",
"       <td>",
"        EMG with 50 to 100 ms discharges; EEG and SEP normal",
"       </td>",
"       <td>",
"        Subcortical-nonsegmental",
"       </td>",
"       <td>",
"        Essential",
"       </td>",
"       <td>",
"        Genetically heterogeneous; DYT11, DYT15 mutations",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Juvenile myoclonic epilepsy",
"       </td>",
"       <td>",
"        Usually generalized",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Occurs from rest",
"       </td>",
"       <td>",
"        EEG with 4 to 6-hertz polyspike and wave discharge",
"       </td>",
"       <td>",
"        Cortical-subcortical",
"       </td>",
"       <td>",
"        Epileptic",
"       </td>",
"       <td>",
"        Genetically heterogeneous; EFHC1 and GABRA1 mutations",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Palatal tremor",
"       </td>",
"       <td rowspan=\"2\">",
"        Palate, larynx, face; usually bilateral",
"       </td>",
"       <td rowspan=\"2\">",
"        Rhythmic",
"       </td>",
"       <td rowspan=\"2\">",
"        Persistent, continues during sleep",
"       </td>",
"       <td rowspan=\"2\">",
"        EMG with &gt;100 ms rhythmic discharges",
"       </td>",
"       <td rowspan=\"2\">",
"        Segmental",
"       </td>",
"       <td>",
"        Symptomatic (secondary) palatal tremor",
"       </td>",
"       <td>",
"        Brainstem pathology in the region of the Guillain-Mollaret triangle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential palatal tremor",
"       </td>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Posthypoxic myoclonus",
"       </td>",
"       <td>",
"        Multifocal and/or generalized",
"       </td>",
"       <td>",
"        Irregular, less often rhythmic",
"       </td>",
"       <td>",
"        Action and reflex",
"       </td>",
"       <td>",
"        EMG discharges &lt;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging",
"       </td>",
"       <td>",
"        Cortical",
"       </td>",
"       <td>",
"        Symptomatic (secondary)",
"       </td>",
"       <td>",
"        Hypoxic brain injury",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Progressive myoclonus epilepsy (PME) and progressive myoclonus ataxia (PMA)",
"       </td>",
"       <td>",
"        Multifocal and/or generalized",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Action and reflex",
"       </td>",
"       <td>",
"        EMG discharges &lt;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging",
"       </td>",
"       <td>",
"        Cortical",
"       </td>",
"       <td>",
"        Symptomatic (secondary)",
"       </td>",
"       <td>",
"        Unverricht-Lundborg disease, Lafora body disease, neuronal ceroid lipofuscinosis, myoclonic epilepsy with ragged red fibers (MERRF), sialidosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Toxic-metabolic myoclonus",
"       </td>",
"       <td>",
"        Multifocal, sometimes generalized",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Rest and action",
"       </td>",
"       <td>",
"        Variable; positive or negative myoclonus; EMG discharges or silence lasting 50 to 200 ms; cortical correlate possible",
"       </td>",
"       <td>",
"        Cortical most common",
"       </td>",
"       <td>",
"        Symptomatic (secondary)",
"       </td>",
"       <td>",
"        Drugs, toxins, organ failure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Neurodegenerative disease",
"       </td>",
"       <td>",
"        Multifocal and worse distally; sometimes generalized",
"       </td>",
"       <td>",
"        Irregular",
"       </td>",
"       <td>",
"        Action most common, then rest and reflex",
"       </td>",
"       <td>",
"        EMG discharges &lt;50 ms; cortical EEG correlate grossly time-locked with EEG back-averaging",
"       </td>",
"       <td>",
"        Cortical",
"       </td>",
"       <td>",
"        Symptomatic",
"       </td>",
"       <td>",
"        Alzheimer disease, dementia with Lewy bodies, Parkinson disease, Huntington disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Creutzfeldt-Jakob disease",
"       </td>",
"       <td>",
"        Focal, multifocal, or generalized",
"       </td>",
"       <td>",
"        Single, irregular, or rhythmic",
"       </td>",
"       <td>",
"        Rest, action, and/or reflex in response to somatosensory stimuli, particularly loud noise (startle)",
"       </td>",
"       <td>",
"        EEG with periodic synchronous biphasic or triphasic sharp wave complexes; EMG discharge &lt;50 ms",
"       </td>",
"       <td>",
"        Cortical",
"       </td>",
"       <td>",
"        Symptomatic (secondary)",
"       </td>",
"       <td>",
"        Prion disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34333=[""].join("\n");
var outline_f33_33_34333=null;
var title_f33_33_34334="Alpha hemolysis";
var content_f33_33_34334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59890&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optochin disk test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 339px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Optochin disk test to differentiate alpha-hemolytic (green) streptococci. Streptococcus pneumoniae is susceptible to optochin as shown by the zone of inhibition around the disk of the culture on the right. Other alpha- hemolytic streptococci (example on left) are resistant to this compound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34334=[""].join("\n");
var outline_f33_33_34334=null;
var title_f33_33_34335="Standard cricothyrotomy step three";
var content_f33_33_34335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71670&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Standard cricothyrotomy step three",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     <font class=\"red\" color=\"black\">",
"      <font color=\"black\">",
"       Incise the cricothyroid membrane transversely.",
"      </font>",
"     </font>",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Custalow CB. Color Atlas of Emergency Department Procedures, Elsevier Saunders, Philadelphia 2005. Copyright &copy;2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_33_34335=[""].join("\n");
var outline_f33_33_34335=null;
